Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593486 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| SCHEMBL10856399 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| SCHEMBL30617339 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| SCHEMBL30530743 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| SCHEMBL15541765 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| SCHEMBL19592042 | 1.00 | TSHR (0.54) | TSHRALDH1A1FABP7FABP5BACE1 | |
| Hydrochloric Acid SCHEMBL30530794 | 0.99 | TSHR (0.56) | TSHRALDH1A1FABP7FABP5BACE1 | |
| Hydrochloric Acid SCHEMBL30617336 | 0.99 | TSHR (0.56) | TSHRALDH1A1FABP7FABP5BACE1 | |
| Hydrochloric Acid SCHEMBL28444146 | 0.99 | TSHR (0.56) | TSHRALDH1A1FABP7FABP5BACE1 | |
| Hydrochloric Acid SCHEMBL15541764 | 0.99 | TSHR (0.56) | TSHRALDH1A1FABP7FABP5BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | TSHR 4413/4885ALDH1A1 3628/4885FABP7 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.